Report cover image

Mucopolysaccharidosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 150 Pages
SKU # FOB19847008

Description

Growth Factors of Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis treatment market size was valued at USD 1.98 billion in 2018, and the market is now projected tgrow from USD 7.96 billion by 2032, exhibiting a CAGR of 10.4% during the forecast period of 2019-2026.

Most enzyme replacement therapies, such as Elaprase, are costly and thus only accessible ta few patients, restricting mucopolysaccharidosis treatments in particularly developing countries. Current approaches tthe treatment dnot reach the brain, thus excluding the neurological manifestations of the condition. This condition fosters a demand for superior therapies taddress the unmet need. Anticipated launches of affordable alternatives are expected tboost the market. Improved treatment outcomes and better accessibility will propel the global mucopolysaccharidosis treatment market growth.

Rising research and development for rare diseases boosts the mucopolysaccharidosis treatment market share, driven by pipeline candidates from companies such as ArmaGen and REGENXBIO. Orphan diseases, including MPS, offer higher potential for blockbuster drugs than conventional treatments. Pharmaceutical firms focus on rare diseases due tfewer requirements for large outcome studies. This trend strengthens market growth and innovation in MPS therapies. Emerging markets for rare disease treatment and diagnosis will alsprobably drive market share-expanding investments in rare disease therapies during the forecast period.

Comprehensive Analysis of Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis treatment market and healthcare industry is rising at an exponential rate due tits market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by treatment, by disease type, by route of administration and by end-user. The treatment includes, Enzyme Replacement Therapy (ERT) and Others. The disease type includes, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IV A, Mucopolysaccharidosis Type VI and Others. The route of administration includes, Intravenous and Intracerebroventricular (ICV). The end-user includes, Hospitals, Specialty Clinics and Others.

The North American mucopolysaccharidosis treatment marketplace accounted for USD 1,019.4 million in 2018 and has a better market proportion. The contribution comes from great diagnosis/treatment rates and reimbursement policies. Superior diagnostic techniques and tools, improved patient consciousness, and comprehension and extended controlled trials and research work are some of the factors that drive the market. The industry players alsplay a key role in the development of the pipeline. Such aspects support that North America is the world’s most preferred destination for MPS treatment.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., SangamTherapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corporation and Others. These market players provide a level-playing competitive landscape.

In February 2020, Lysogene, a main scientific biopharmaceutical organization, bagged the FDA fast-track label for the LYS-SAF302 gene therapy pipeline in MPS IIIA or Sanfilippsyndrome.

Segmentation Table

Global Mucopolysaccharidosis Treatment Market Scope

Study Period 2015-2026

Base Year 2018

Forecast Period 2019-2026

Growth Rate CAGR of 10.4% from 2019 t2026

Historical Period 2015-2017

Unit Value (USD billion)

Segmentation By Treatment, Disease Type, Route of Administration, End User, and Geography

By Treatment
  • Enzyme Replacement Therapy (ERT)
  • Others
By Disease Type
  • Mucopolysaccharidosis Type I
  • Mucopolysaccharidosis Type II
  • Mucopolysaccharidosis Type IV A
  • Mucopolysaccharidosis Type VI
  • Others
By Route of Administration
  • Intravenous
  • Intracerebroventricular (ICV)
By End User
  • Hospitals
  • Specialty Clinics
  • Others
By Geography
  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
  • Rest of the World


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

150 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Key Mucopolysaccharidosis Types - by key regions (2018)
4.2. Pipeline Analysis
4.3. Key Industry Developments
4.4. Regulatory Scenario- by Key Regions
4.5. Overview of Emerging Treatments for Mucopolysaccharidosis
4.6. Reimbursement Scenario - by Key Regions
5. Global Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Treatment
5.2.1. Enzyme Replacement Therapy (ERT)
5.2.2. Others
5.3. Market Analysis, Insights and Forecast – By Disease Type
5.3.1. Mucopolysaccharidosis Type I
5.3.2. Mucopolysaccharidosis Type II
5.3.3. Mucopolysaccharidosis Type IV A
5.3.4. Mucopolysaccharidosis Type VI
5.3.5. Others
5.4. Market Analysis, Insights and Forecast – By Route of Administration
5.4.1. Intravenous
5.4.2. Intracerebroventricular (ICV)
5.5. Market Analysis, Insights and Forecast – By End User
5.5.1. Hospitals
5.5.2. Specialty Clinics
5.5.3. Others
5.6. Market Analysis, Insights and Forecast – By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia pacific
5.6.4. Rest of the World
6. North America Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Treatment
6.2.1. Enzyme Replacement Therapy (ERT)
6.2.2. Others
6.3. Market Analysis – By Disease Type
6.3.1. Mucopolysaccharidosis Type I
6.3.2. Mucopolysaccharidosis Type II
6.3.3. Mucopolysaccharidosis Type IV A
6.3.4. Mucopolysaccharidosis Type VI
6.3.5. Others
6.4. Market Analysis – By Route of Administration
6.4.1. Intravenous
6.4.2. Intracerebroventricular (ICV)
6.5. Market Analysis – By End User
6.5.1. Hospitals
6.5.2. Specialty Clinics
6.5.3. Others
6.6. Market Analysis – By Country
6.6.1. U.S.
6.6.2. Canada
7. Europe Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis – By Treatment
7.2.1. Enzyme Replacement Therapy (ERT)
7.2.2. Others
7.3. Market Analysis – By Disease Type
7.3.1. Mucopolysaccharidosis Type I
7.3.2. Mucopolysaccharidosis Type II
7.3.3. Mucopolysaccharidosis Type IV A
7.3.4. Mucopolysaccharidosis Type VI
7.3.5. Others
7.4. Market Analysis – By Route of Administration
7.4.1. Intravenous
7.4.2. Intracerebroventricular (ICV)
7.5. Market Analysis – By End User
7.5.1. Hospitals
7.5.2. Specialty Clinics
7.5.3. Others
7.6. Market Analysis – By Country/ sub-region
7.6.1. U.K.
7.6.2. Germany
7.6.3. France
7.6.4. Spain
7.6.5. Italy
7.6.6. Rest of Europe
8. Asia Pacific Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis – By Treatment
8.2.1. Enzyme Replacement Therapy (ERT)
8.2.2. Others
8.3. Market Analysis – By Disease Type
8.3.1. Mucopolysaccharidosis Type I
8.3.2. Mucopolysaccharidosis Type II
8.3.3. Mucopolysaccharidosis Type IV A
8.3.4. Mucopolysaccharidosis Type VI
8.3.5. Others
8.4. Market Analysis – By Route of Administration
8.4.1. Intravenous
8.4.2. Intracerebroventricular (ICV)
8.5. Market Analysis – By End User
8.5.1. Hospitals
8.5.2. Specialty Clinics
8.5.3. Others
8.6. Market Analysis – By Country/ sub-region
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Rest of Asia Pacific
9. Rest of the World Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis – By Treatment
9.2.1. Enzyme Replacement Therapy (ERT)
9.2.2. Others
9.3. Market Analysis – By Disease Type
9.3.1. Mucopolysaccharidosis Type I
9.3.2. Mucopolysaccharidosis Type II
9.3.3. Mucopolysaccharidosis Type IV A
9.3.4. Mucopolysaccharidosis Type VI
9.3.5. Others
9.4. Market Analysis – By Route of Administration
9.4.1. Intravenous
9.4.2. Intracerebroventricular (ICV)
9.5. Market Analysis – By End User
9.5.1. Hospitals
9.5.2. Specialty Clinics
9.5.3. Others
10. Competitive Analysis
10.1. Key Industry Developments
10.2. Global Market Share Analysis (2017)
10.3. Competition Dashboard
10.4. Comparative Analysis – Major Players
10.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
10.5.1. Shire (Takeda Pharmaceutical Company Limited)
10.5.1.1. Overview,
10.5.1.2. Products & services,
10.5.1.3. SWOT analysis,
10.5.1.4. Recent developments,
10.5.1.5. strategies,
10.5.1.6. financials (based on availability)
10.5.2. Denali Therapeutics
10.5.2.1. Overview,
10.5.2.2. Products & services,
10.5.2.3. SWOT analysis,
10.5.2.4. Recent developments,
10.5.2.5. strategies,
10.5.2.6. financials (based on availability)
10.5.3. ArmaGen
10.5.3.1. Overview,
10.5.3.2. Products & services,
10.5.3.3. SWOT analysis,
10.5.3.4. Recent developments,
10.5.3.5. strategies,
10.5.3.6. financials (based on availability)
10.5.4. REGENXBIO Inc.
10.5.4.1. Overview,
10.5.4.2. Products & services,
10.5.4.3. SWOT analysis,
10.5.4.4. Recent developments,
10.5.4.5. strategies,
10.5.4.6. financials (based on availability)
10.5.5. Sangamo Therapeutics
10.5.5.1. Overview,
10.5.5.2. Products & services,
10.5.5.3. SWOT analysis,
10.5.5.4. Recent developments,
10.5.5.5. strategies,
10.5.5.6. financials (based on availability)
10.5.6. BioMarin
10.5.6.1. Overview,
10.5.6.2. Products & services,
10.5.6.3. SWOT analysis,
10.5.6.4. Recent developments,
10.5.6.5. strategies,
10.5.6.6. financials (based on availability)
10.5.7. Lysogene
10.5.7.1. Overview,
10.5.7.2. Products & services,
10.5.7.3. SWOT analysis,
10.5.7.4. Recent developments,
10.5.7.5. strategies,
10.5.7.6. financials (based on availability)
10.5.8. Abeona Therapeutics Inc.
10.5.8.1. Overview,
10.5.8.2. Products & services,
10.5.8.3. SWOT analysis,
10.5.8.4. Recent developments,
10.5.8.5. strategies,
10.5.8.6. financials (based on availability)
10.5.9. Ultragenyx Pharmaceutical
10.5.9.1. Overview,
10.5.9.2. Products & services,
10.5.9.3. SWOT analysis,
10.5.9.4. Recent developments,
10.5.9.5. strategies,
10.5.9.6. financials (based on availability)
10.5.10. Genzyme Corporation
10.5.10.1. Overview,
10.5.10.2. Products & services,
10.5.10.3. SWOT analysis,
10.5.10.4. Recent developments,
10.5.10.5. strategies,
10.5.10.6. financials (based on availability)
11. Competitive Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us